Review emails being sent to your clients on your behalf
As the developments around the coronavirus (COVID-19) continue to evolve, it is important to be sensitive with communications to your clients. To ensure your customers and prospects receive relevant information during this time of uncertainty, be sure to evaluate what automated campaigns you are opted into in MoxiCampaigns.
Pausing Campaigns
You can choose to temporarily pause any of your campaigns within MoxiCampaigns by following these steps:
- Click on the Campaigns (Beta) tab at the top of your MoxiEngage dashboard
- Select My Campaigns
- Click on the campaign title you’d like to temporarily pause
- Click on the Stop Campaign button
Editing Campaigns
You can remove or add a touchpoint within a scheduled campaign by following these steps.
- Click on Campaigns (Beta) tab at the top of your MoxiEngage dashboard
- Select My Campaigns
- Click on Edit on the right of the campaign you’d like to edit
- To remove –
- Click on the trashcan icon next to the scheduled touchpoint you’d like to remove
- To add a touchpoint –
- Click Add Touchpoint
- Select the touchpoint you’d like to add from the dropdown menu
- Enter the date you’d like the additional touchpoint sent
- Click on the Next Preview button
- Click Save
What to Send Now
Long & Foster has added a new campaign called “Special Item of Value Letter ” to MoxiCampaigns. If you were previously opted into “Special Item of Value Letter – Coronavirus”, please be sure to run this new campaign instead.
This is a great way to keep in touch with your clients and prospects, while providing them regular updates about the market today surrounding the coronavirus. Our newsletter campaign within MoxiCampaigns also will feature relevant information about today’s environment, should you want to send that campaign.
Please note: you should also evaluate and review other direct mail campaigns if you are currently subscribed to any.
As always, your well-being and business continuity are our top priority throughout this situation. We will continue to monitor developments around COVID-19, and we’ll keep you updated.